HR Execs on the Move

AsclepiX Therapeutics

www.asclepix.com

 
AsclepiX Therapeutics is revolutionizing the treatment of retinal diseases and cancer with a singular focus on the design, development, and delivery of novel peptides with the power to inhibit proven key disease pathways.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.asclepix.com
  • 185 Hudson Street Suite 2500
    Jersey City, NJ USA 07311
  • Phone: N/A

Executives

Name Title Contact Details
Jill Vazzano Tierney
Director of Finance Profile
Kevin Slawin
Chief Executive Officer Profile

Similar Companies

BTI Products

BTI Products is a Bayfield, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SeniorBridge Family

SeniorBridge Family is a New York, NY-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

GRAIL

GRAIL`s mission is to detect cancer early, when it can be cured.

Audentes Therapeutics

Audentes is a biotechnology company committed to the development and commercialization of innovative new medicines for people with serious, rare muscle diseases. We are a passionate, energetic team driven by the goals of improving the lives of patients and building a successful business. We take pride in strong, global relationships with the patient, research, and medical communities.

Arvinas

Arvinas is a pharmaceutical company focused on developing new small molecules ‒ known as PROTACs (PROteolysis TArgeting Chimeras) ‒ aimed at degrading disease-causing cellular proteins via proteolysis. Based on innovative research conducted at Yale University by Dr. Craig Crews, Founder and Chief Scientific Advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. The proprietary PROTAC-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting “undruggable” as well as “druggable” elements of the proteome. This greatly expands the ability to create drugs for many new, previously unapproachable targets.